EX2001 | Aug 18, 2025 | EXHIBIT | PATENT OWNER |
EX2002 | Aug 18, 2025 | EXHIBIT | PATENT OWNER |
EX2003 | Aug 18, 2025 | EXHIBIT | PATENT OWNER |
EX2004 | Aug 18, 2025 | EXHIBIT | PATENT OWNER |
EX2005 | Aug 18, 2025 | EXHIBIT | PATENT OWNER |
EX2006 | Aug 18, 2025 | EXHIBIT | PATENT OWNER |
EX2007 | Aug 18, 2025 | EXHIBIT | PATENT OWNER |
EX2008 | Aug 18, 2025 | EXHIBIT | PATENT OWNER |
EX2009 | Aug 18, 2025 | EXHIBIT | PATENT OWNER |
EX2010 | Aug 18, 2025 | EXHIBIT | PATENT OWNER |
EX2011 | Aug 18, 2025 | EXHIBIT | PATENT OWNER |
EX2012 | Aug 18, 2025 | EXHIBIT | PATENT OWNER |
EX2013 | Aug 18, 2025 | EXHIBIT | PATENT OWNER |
EX2014 | Aug 18, 2025 | EXHIBIT | PATENT OWNER |
EX2015 | Aug 18, 2025 | EXHIBIT | PATENT OWNER |
EX2016 | Aug 18, 2025 | EXHIBIT | PATENT OWNER |
EX2017 | Aug 18, 2025 | EXHIBIT | PATENT OWNER |
EX2018 | Aug 18, 2025 | EXHIBIT | PATENT OWNER |
EX2019 | Aug 18, 2025 | EXHIBIT | PATENT OWNER |
EX2020 | Aug 18, 2025 | EXHIBIT | PATENT OWNER |
Patent Owner's Discretionary Denial Brief | Aug 18, 2025 | PAPER | PATENT OWNER |
EXPUNGED | Jun 18, 2025 | PAPER | BOARD |
Notice: Notice filing date accorded | Jun 18, 2025 | PAPER | BOARD |
Notice: Patent Owner's Mandatory Notice | Jun 18, 2025 | PAPER | PATENT OWNER |
Notice: Patent Owner's Power of Attorney | Jun 18, 2025 | PAPER | PATENT OWNER |
Almoazen '437 Patent, U.S. Patent No. 11,021,437 B2. | May 16, 2025 | EXHIBIT | PETITIONER |
Truelove 1, U.S. Patent No. 3,809,714 | May 16, 2025 | EXHIBIT | PETITIONER |
Ashraf, “Considerations in Developing Sublingual Tablets – An Overview" | May 16, 2025 | EXHIBIT | PETITIONER |
Fuchs, U.S. Patent No. 4,136,145. | May 16, 2025 | EXHIBIT | PETITIONER |
Almoazen '437 Patent File History, U.S. App. Ser. No. 16/347,625. | May 16, 2025 | EXHIBIT | PETITIONER |
Truelove 2, U.S. Patent No. 3,825,583. | May 16, 2025 | EXHIBIT | PETITIONER |
Truelove 4, “Prodrug Approaches to , , , Novel Epinephrine Prodrug” | May 16, 2025 | EXHIBIT | PETITIONER |
Truelove 3, U.S. Patent No. 3,868,461. | May 16, 2025 | EXHIBIT | PETITIONER |
The Merck Index, 12th Ed., 1996, p. 613. | May 16, 2025 | EXHIBIT | PETITIONER |
USP certificate for epinephrine, dated 14 Aug 2017. | May 16, 2025 | EXHIBIT | PETITIONER |
EpiPen Information | May 16, 2025 | EXHIBIT | PETITIONER |
Almoazen ‘437 Patent Provisional Application, Ser. No. 62,421,316. | May 16, 2025 | EXHIBIT | PETITIONER |
Almoazen PCT Application, WO2018/089570 A1 (PCT/US2017/060761). | May 16, 2025 | EXHIBIT | PETITIONER |
Florence, “Physicochemical Principles of Pharmacy”. | May 16, 2025 | EXHIBIT | PETITIONER |
Bodor, U.S. Patent No. 4,145,441. | May 16, 2025 | EXHIBIT | PETITIONER |
Rawas-Qalaji, U.S. Patent Application Publication No. US 2007/0202163 A1. | May 16, 2025 | EXHIBIT | PETITIONER |
Ettmayer, “Lessons Learned from Marketed and Investigational Prodrug". | May 16, 2025 | EXHIBIT | PETITIONER |
Rautio, “Prodrugs: design and clinical applications”. | May 16, 2025 | EXHIBIT | PETITIONER |
Silverman, “Prodrugs and drug delivery systems”. | May 16, 2025 | EXHIBIT | PETITIONER |
Schobel, U.S. Patent No. 11,191,737 B2. | May 16, 2025 | EXHIBIT | PETITIONER |
Almoazen Paper, “Development of a fast dissolving film of epinephrine ...". | May 16, 2025 | EXHIBIT | PETITIONER |
Baldessarini, “Hydrolysis of diester prodrugs of apomorphine”. | May 16, 2025 | EXHIBIT | PETITIONER |
Kristoffersson, “Drug latentiation of terbutaline”. | May 16, 2025 | EXHIBIT | PETITIONER |
Christrup, “Improvement of buccal delivery ... using the prodrug approach” | May 16, 2025 | EXHIBIT | PETITIONER |
Lieberman, “The diagnosis and management of anaphylaxis practice parameter" | May 16, 2025 | EXHIBIT | PETITIONER |
den Daas, “Improvement of the oral bioavailability . . . ester prodrugs". | May 16, 2025 | EXHIBIT | PETITIONER |
Hansen 1991, “Ketobemidone prodrugs for buccal delivery”. | May 16, 2025 | EXHIBIT | PETITIONER |
Hansen 1992, “Ketobemidone prodrugs for buccal delivery ...". | May 16, 2025 | EXHIBIT | PETITIONER |
Markup of EX1001 showing EX1022 contribution. | May 16, 2025 | EXHIBIT | PETITIONER |
Roche, “Design of biopharmaceutical properties through prodrugs ...". | May 16, 2025 | EXHIBIT | PETITIONER |
Markup of EX1022 showing material found in EX1001. | May 16, 2025 | EXHIBIT | PETITIONER |
Morrison and Boyd, “Organic Chemistry”, Sections 18.1-18-4. | May 16, 2025 | EXHIBIT | PETITIONER |
Streitwieser, “Introduction to Organic Chemistry”, excerpts. | May 16, 2025 | EXHIBIT | PETITIONER |
Stepensky, “Long-Term Stability Study of L-Adrenaline Injections ...". | May 16, 2025 | EXHIBIT | PETITIONER |
Rautio II, “Prodrugs—from Serendipity to Rational Design”. | May 16, 2025 | EXHIBIT | PETITIONER |
Senel, “Drug permeation enhancement via buccal route ...". | May 16, 2025 | EXHIBIT | PETITIONER |
Kohn, “Clinical Comparison of Dipivalyl Epinephrine and Epinephrine ...". | May 16, 2025 | EXHIBIT | PETITIONER |
Journal of Medicinal Chemistry (JMC) Manuscript Requirements | May 16, 2025 | EXHIBIT | PETITIONER |
Declaration of Jarkko Rautio, Ph.D. | May 16, 2025 | EXHIBIT | PETITIONER |
Declaration of Nicholas A. Meanwell, Ph.D. | May 16, 2025 | EXHIBIT | PETITIONER |
Notice: Power of Attorney | May 16, 2025 | PAPER | PETITIONER |
Petition: as filed | May 16, 2025 | PAPER | PETITIONER |